Concepedia
Statistics
Publications
29
Citations
2.4K
H-Index
21
Active since
1987
Affiliations
Amgen (United States)(Current)
Yale University
Takeda (United States)
Howard Hughes Medical Institute
Temple University
John Newcomb is an author at Amgen (United States) specializing in medicine, drug discovery, and pharmacology.
Top concepts
MedicineDrug DiscoveryPharmacologyNatural SciencesMedicinal ChemistryImmunologyBiochemistryCell BiologyDrug DevelopmentPharmacotherapy
Publications per year
1987–2020
A small-molecule inhibitor of the ubiquitin activating enzyme for cancer treatment
Marc L. Hyer, Michael A. Milhollen, Jeff Ciavarri et al. · Nature Medicine · 2018 · 414 citations
Medicine, Anti-cancer Agent, Small-molecule Inhibitor +8
HLA-DR molecules from an antigen-processing mutant cell line are associated with invariant chain peptides
Janice M. Riberdy, John Newcomb, Michael J. Surman et al. · Nature · 1992 · 379 citations
Histocompatibility, Human Leukocyte Antigen, Invariant Chain Peptides +12
Structural analysis of the lymphocyte-specific kinase Lck in complex with non-selective and Src family selective kinase inhibitors
Xiaotian Zhu, Joseph L. Kim, John Newcomb et al. · Structure · 1999 · 255 citations · Full text
Signal Transduction, Receptor Tyrosine Kinase, Molecular Biology +8
Probing the roles of SUMOylation in cancer cell biology by using a selective SAE inhibitor
Xingyue He, Jessica Riceberg, Teresa A. Soucy et al. · Nature Chemical Biology · 2017 · 223 citations
Selective Sae Inhibitor, Oncogenic Agent, Medicine +10
Invariant chain cleavage and peptide loading in major histocompatibility complex class II vesicles.
Sebastián Amigorena, Paul Webster, James R. Drake et al. · The Journal of Experimental Medicine · 1995 · 145 citations · Full text
Proteinlipid Interaction, Immunology, Molecular Biology +20
Rows per page
1–5 of 29